HUE038467T2 - Varicella zoster vírus oltóanyag - Google Patents

Varicella zoster vírus oltóanyag

Info

Publication number
HUE038467T2
HUE038467T2 HUE10188256A HUE10188256A HUE038467T2 HU E038467 T2 HUE038467 T2 HU E038467T2 HU E10188256 A HUE10188256 A HU E10188256A HU E10188256 A HUE10188256 A HU E10188256A HU E038467 T2 HUE038467 T2 HU E038467T2
Authority
HU
Hungary
Prior art keywords
virus vaccine
zoster virus
varicella zoster
varicella
vaccine
Prior art date
Application number
HUE10188256A
Other languages
English (en)
Hungarian (hu)
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE038467(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HUE038467T2 publication Critical patent/HUE038467T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE10188256A 2005-03-03 2006-03-01 Varicella zoster vírus oltóanyag HUE038467T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine

Publications (1)

Publication Number Publication Date
HUE038467T2 true HUE038467T2 (hu) 2018-10-29

Family

ID=34430592

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE10188256A HUE038467T2 (hu) 2005-03-03 2006-03-01 Varicella zoster vírus oltóanyag
HUE10188215A HUE038468T2 (hu) 2005-03-03 2006-03-01 Varicella zoster vírus oltóanyag
HUE10188214A HUE032544T2 (en) 2005-03-03 2006-03-01 Varicella Zoster virus vaccine
HUS1800038C HUS1800038I1 (hu) 2005-03-03 2018-09-20 Varicella zoster vírus oltóanyag

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUE10188215A HUE038468T2 (hu) 2005-03-03 2006-03-01 Varicella zoster vírus oltóanyag
HUE10188214A HUE032544T2 (en) 2005-03-03 2006-03-01 Varicella Zoster virus vaccine
HUS1800038C HUS1800038I1 (hu) 2005-03-03 2018-09-20 Varicella zoster vírus oltóanyag

Country Status (35)

Country Link
US (3) US20080171079A1 (en:Method)
EP (4) EP2281831B1 (en:Method)
JP (2) JP5420842B2 (en:Method)
KR (2) KR20140006115A (en:Method)
CN (2) CN103028113B (en:Method)
AR (2) AR052498A1 (en:Method)
AU (1) AU2006222225B2 (en:Method)
BE (1) BE2018C035I2 (en:Method)
BR (1) BRPI0607840B1 (en:Method)
CA (2) CA2882255C (en:Method)
CY (5) CY1116108T1 (en:Method)
DK (4) DK2301955T3 (en:Method)
EA (1) EA011884B1 (en:Method)
ES (4) ES2532803T3 (en:Method)
GB (1) GB0504436D0 (en:Method)
HR (4) HRP20150142T1 (en:Method)
HU (4) HUE038467T2 (en:Method)
IL (1) IL185442A (en:Method)
LT (4) LT2281830T (en:Method)
LU (1) LUC00087I2 (en:Method)
MA (1) MA29714B1 (en:Method)
MX (2) MX2007010626A (en:Method)
MY (1) MY148464A (en:Method)
NL (1) NL300951I2 (en:Method)
NO (2) NO341841B1 (en:Method)
NZ (1) NZ561075A (en:Method)
PE (2) PE20061287A1 (en:Method)
PL (4) PL2281830T3 (en:Method)
PT (4) PT2301955T (en:Method)
SI (4) SI2281831T1 (en:Method)
TR (2) TR201809397T4 (en:Method)
TW (1) TWI403517B (en:Method)
UA (1) UA94900C2 (en:Method)
WO (1) WO2006094756A2 (en:Method)
ZA (1) ZA200707144B (en:Method)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2729011A1 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Varicella zoster virus-virus like particles (vlps) and antigens
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
US20130171241A1 (en) 2010-07-06 2013-07-04 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
CA3169291A1 (en) 2010-07-06 2012-01-12 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of rna
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
SMT202200497T1 (it) 2010-08-31 2023-01-13 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogeno
MX363307B (es) 2010-10-11 2019-03-20 Novartis Ag Star Plataformas para suministro de antigenos.
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3053591A4 (en) * 2013-10-03 2017-04-19 Nitto Denko Corporation Injectable vaccine composition
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
CA2970840A1 (en) * 2014-12-18 2016-06-23 Glaxosmithkline Biologicals S.A. Vaccine composition comprising truncated varicella zoster virus glycoprotein e antigen
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
HRP20220872T1 (hr) 2015-10-22 2022-12-23 Modernatx, Inc. Cjepiva protiv respiratornih virusa
TW201729838A (zh) * 2015-10-22 2017-09-01 現代公司 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
SG11201803594TA (en) 2015-11-06 2018-05-30 Adjuvance Technologies Inc Triterpene saponin analogues
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
EP3545972A4 (en) * 2016-11-25 2020-05-13 Mogam Institute For Biomedical Research VARICELLA AND ZONA VIRUS VACCINE
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
KR102034234B1 (ko) * 2016-12-26 2019-10-18 재단법인 목암생명과학연구소 대상포진 백신 조성물
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
SG10202108075YA (en) * 2017-04-25 2021-09-29 Adjuvance Technologies Inc Triterpene saponin analogues
US20200164065A1 (en) * 2017-04-25 2020-05-28 Adjuvance Technologies, Inc. Triterpene saponin analogues
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
EP3812394A4 (en) 2018-05-23 2022-03-23 Mogam Institute for Biomedical Research ANTIGEN VARIANT OF VARICELLA ZOSTER VIRUS AND USE THEREOF
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
WO2020063370A2 (zh) * 2018-09-27 2020-04-02 武汉博沃生物科技有限公司 免疫组合物及其制备方法与应用
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN115177724A (zh) * 2019-06-28 2022-10-14 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
WO2021115410A1 (zh) * 2019-12-13 2021-06-17 南京远大赛威信生物医药有限公司 免疫刺激组合物及其用途
CA3173743A1 (en) * 2020-02-28 2021-09-02 Celltrion Inc. Varicella zoster virus fusion protein and immunogenic composition comprising same
US20230287038A1 (en) 2020-08-07 2023-09-14 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
US12527859B2 (en) 2020-09-11 2026-01-20 Eubiologics Co., Ltd. Vaccine composition for chickenpox or Varicella Zoster and method of using same
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
EP4416274A2 (en) 2021-10-15 2024-08-21 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CN116327912A (zh) * 2021-12-23 2023-06-27 上海泽润生物科技有限公司 带状疱疹疫苗组合物
CN116350770B (zh) * 2021-12-28 2024-07-12 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production
CN116655748B (zh) * 2023-02-28 2024-07-26 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
CN118240844B (zh) * 2024-05-27 2024-12-13 北京悦康科创医药科技股份有限公司 带状疱疹mRNA疫苗及其制备方法和应用
WO2026006687A1 (en) * 2024-06-28 2026-01-02 Orbital Therapeutics, Inc. Circular rna compositions and uses thereof for diseases caused by varicella-zoster virus
CN120081913B (zh) * 2025-05-08 2025-08-12 江苏华诺泰生物医药科技有限公司 一种重组带状疱疹病毒原液的纯化方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (en:Method) 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE119939T1 (de) 1989-06-27 1995-04-15 Smithkline Beecham Biolog Verbindungen.
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
EP0671948B1 (en) * 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
JP4562812B2 (ja) 1992-07-17 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション 帯状疱疹の予防または水痘関連ヘルペス後神経痛の緩和方法
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2267100T5 (es) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
CN1326564C (zh) 1997-04-01 2007-07-18 科里克萨有限公司 单磷酰基脂质a的水性免疫佐剂组合物
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
JP2004511527A (ja) 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
US20080171079A1 (en) 2008-07-17
NO20074392L (no) 2007-11-27
ZA200707144B (en) 2009-11-25
EP1858917B1 (en) 2014-12-24
EP2281830A2 (en) 2011-02-09
HRP20180989T1 (hr) 2018-08-10
CY2018025I2 (el) 2018-12-12
US20110104260A1 (en) 2011-05-05
EA011884B1 (ru) 2009-06-30
KR20140006115A (ko) 2014-01-15
ES2675054T3 (es) 2018-07-06
CY1120347T1 (el) 2018-12-12
AU2006222225B2 (en) 2012-08-16
HRP20150142T1 (hr) 2015-05-22
ES2532803T3 (es) 2015-03-31
CY2018025I1 (el) 2018-12-12
WO2006094756A3 (en) 2007-02-15
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
KR20070110413A (ko) 2007-11-16
PL2301955T3 (pl) 2018-08-31
EP2301955B1 (en) 2018-04-18
DK2281831T3 (en) 2018-06-14
US7939084B1 (en) 2011-05-10
CY1118629T1 (el) 2017-07-12
JP5840167B2 (ja) 2016-01-06
NO341841B1 (no) 2018-02-05
PT2281831T (pt) 2018-06-15
EP1858917B8 (en) 2015-05-06
SI1858917T1 (sl) 2015-03-31
DK2281830T3 (en) 2017-03-20
PL1858917T3 (pl) 2015-05-29
TW200643028A (en) 2006-12-16
US20110045059A1 (en) 2011-02-24
NZ561075A (en) 2009-06-26
CA2600905C (en) 2015-05-05
CY1116108T1 (el) 2017-02-08
CY1121211T1 (el) 2020-05-29
EP2301955A2 (en) 2011-03-30
EP2281830B1 (en) 2016-12-21
AU2006222225A1 (en) 2006-09-14
JP5420842B2 (ja) 2014-02-19
SI2281831T1 (en) 2018-07-31
HUE038468T2 (hu) 2018-10-29
PL2281830T3 (pl) 2017-06-30
NL300951I2 (nl) 2020-08-31
PT2281830T (pt) 2017-02-24
CN101189254B (zh) 2013-05-22
PE20100658A1 (es) 2010-10-23
EP1858917A2 (en) 2007-11-28
EP2301955A3 (en) 2011-11-16
MX346865B (es) 2017-04-04
DK1858917T3 (da) 2015-02-02
HK1111427A1 (en) 2008-08-08
IL185442A0 (en) 2008-01-06
PL2281831T3 (pl) 2018-08-31
BE2018C035I2 (en:Method) 2025-09-05
HUE032544T2 (en) 2017-10-30
CN101189254A (zh) 2008-05-28
CA2882255A1 (en) 2006-09-14
MY148464A (en) 2013-04-30
SI2301955T1 (en) 2018-07-31
EP2281831A3 (en) 2011-11-16
GB0504436D0 (en) 2005-04-06
DK2301955T3 (en) 2018-06-14
KR101357204B1 (ko) 2014-02-06
CA2600905A1 (en) 2006-09-14
NL300951I1 (nl) 2018-09-26
WO2006094756A2 (en) 2006-09-14
HUS1800038I1 (hu) 2018-10-29
LT2301955T (lt) 2018-07-10
IL185442A (en) 2013-07-31
HRP20170081T1 (hr) 2017-03-24
TWI403517B (zh) 2013-08-01
MA29714B1 (fr) 2008-09-01
HRP20180988T1 (hr) 2018-08-10
ES2675055T3 (es) 2018-07-06
EP2281831A2 (en) 2011-02-09
AR107285A2 (es) 2018-04-18
CN103028113A (zh) 2013-04-10
SI2281830T1 (sl) 2017-03-31
BRPI0607840A2 (pt) 2009-06-13
PT2301955T (pt) 2018-06-18
JP2008531637A (ja) 2008-08-14
BRPI0607840B1 (pt) 2021-06-29
LTC2281831I2 (lt) 2020-08-25
MX2007010626A (es) 2007-10-16
EA200701632A1 (ru) 2008-02-28
PT1858917E (pt) 2015-02-24
LTPA2018012I1 (lt) 2018-11-12
ES2618037T3 (es) 2017-06-20
TR201809393T4 (tr) 2018-07-23
EP2281831B1 (en) 2018-04-18
LUC00087I2 (en:Method) 2018-11-26
LT2281831T (lt) 2018-07-10
LT2281830T (lt) 2017-02-10
CN103028113B (zh) 2015-05-20
CA2882255C (en) 2018-03-27
PE20061287A1 (es) 2006-12-07
JP2013144710A (ja) 2013-07-25
NO2018033I1 (no) 2018-09-20
AR052498A1 (es) 2007-03-21
EP2281830A3 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
HUS1800038I1 (hu) Varicella zoster vírus oltóanyag
PL1926496T3 (pl) Szczepionka przeciw PCV-2
IL192041A0 (en) Synthetic genomes
AP2008004486A0 (en) Pyrimidine derivatives
ZA200810826B (en) Recombinant vaccine against bluetongue virus
PL1860468T3 (pl) Arkusz retroodblaskowy
GB0706912D0 (en) Novel viral vaccines
ZA200906115B (en) Antibodies specific for Varicella Zoster Virus
GB0519245D0 (en) Purine compounds
GB2427113B (en) Virus deactivation unit
GB0709408D0 (en) Anti-col herpes virus compounds
GB0514616D0 (en) Tile spacer
GB0522684D0 (en) Oncolytic viruses
GB0517835D0 (en) DNA viral infections
GB0508061D0 (en) RNA viruses
AU2005902198A0 (en) Synthetic hepatitis C vaccines
GB0517617D0 (en) Treatment using herpes simplex virus
GB0518305D0 (en) Adjuvanted vaccine
GB0501582D0 (en) Hepatitis c virus replication system
IL191977A0 (en) Improved influenza vaccine
HK1126113A (en) Vaccine
HK1113908A (en) Vaccine
HK1113742A (en) Vaccine
AU2005905791A0 (en) Vaccine
GB0703074D0 (en) Viral attachment